Tai Sin Electric Limited (SGX:500)

Ligand Pharmaceuticals Balance Sheet

Financials in millions SGD. Fiscal year is July - June.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020
Cash & Equivalents	36.24	27.42	32	29.2	39.33	33.5
Cash & Short-Term Investments	36.24	27.42	32	29.2	39.33	33.5
Cash Growth	39.41%	-14.33%	9.61%	-25.77%	17.40%	99.15%
Accounts Receivable	122.7	111.9	95.04	112.69	93.41	59.93
Other Receivables	9.52	7.92	5.65	3.88	5	5.27
Receivables	132.23	119.81	100.69	116.58	98.42	65.2
Inventory	113.14	103.37	101.17	98.81	69.94	78.92
Other Current Assets	0.49	0.74	2.42	0.16	7.4	3.08
Total Current Assets	282.09	251.34	236.28	244.74	215.08	180.7
Property, Plant & Equipment	48.36	48.23	49.35	52.87	54.23	49.28
Long-Term Investments	13.16	12.42	12.05	11.41	10.49	10.2
Goodwill	0.13	0.13	0.13	-	-	-
Other Intangible Assets	-	-	-	-	-	0.16
Long-Term Deferred Tax Assets	0.38	0.78	1.29	1.85	3.4	0.09
Other Long-Term Assets	2.85	2.77	2.98	4.83	10.12	2.95
Total Assets	346.96	315.66	302.07	315.71	293.31	243.38
Accounts Payable	31.22	23.39	23.61	38.7	28.54	16.03
Short-Term Debt	-	43.31	29.21	25.87	10.34	20.55
Current Portion of Long-Term Debt	62.87	4	4.32	5.5	7.4	-
Current Portion of Leases	1.24	1.36	1.2	0.83	0.91	1.14
Current Income Taxes Payable	4.47	3.21	3.04	2.75	7.14	2.22
Current Unearned Revenue	5.58	4.57	3.18	2.48	1.58	1.2
Other Current Liabilities	12.29	14.42	18.77	24.08	33.04	9.15
Total Current Liabilities	117.66	94.24	83.32	100.2	88.95	50.29
Long-Term Debt	-	-	-	-	0.44	-
Long-Term Leases	8.44	11.1	10.99	10.85	10.76	9.61
Long-Term Deferred Tax Liabilities	1.49	1.47	0.81	0.91	0.95	1.25
Other Long-Term Liabilities	0.2	0.2	0.2	0.19	0.19	0.16
Total Liabilities	127.8	107.01	95.32	112.14	101.29	61.31
Common Stock	63.71	63.71	63.71	63.71	63.71	63.71
Retained Earnings	159.07	150.57	146.79	140.94	129.29	118.91
Treasury Stock	-0.95	-0.95	-0.95	-0.95	-0.95	-0.95
Comprehensive Income & Other	-4.42	-6.45	-4.75	-2.01	-1.81	-1.17
Total Common Equity	217.42	206.88	204.81	201.69	190.24	180.5
Minority Interest	1.74	1.77	1.95	1.88	1.78	1.57
Shareholders' Equity	219.16	208.65	206.76	203.57	192.02	182.07
Total Liabilities & Equity	346.96	315.66	302.07	315.71	293.31	243.38
Total Debt	72.55	59.77	45.72	43.04	29.84	31.3
Net Cash (Debt)	-36.31	-32.35	-13.72	-13.84	9.49	2.21
Net Cash Growth	-	-	-	-	330.16%	-
Net Cash Per Share	-0.08	-0.07	-0.03	-0.03	0.02	0.00
Filing Date Shares Outstanding	460.26	460.26	460.26	460.26	460.26	460.26
Total Common Shares Outstanding	460.26	460.26	460.26	460.26	460.26	460.26
Working Capital	164.42	157.09	152.95	144.54	126.13	130.41
Book Value Per Share	0.47	0.45	0.44	0.44	0.41	0.39
Tangible Book Value	217.29	206.76	204.68	201.69	190.24	180.34
Tangible Book Value Per Share	0.47	0.45	0.44	0.44	0.41	0.39
Land	-	1.82	1.83	2	2.05	2.06
Buildings	-	34.6	34.66	34.48	34.45	34.49
Machinery	-	63.8	60.79	58.36	55.67	54.27
Construction In Progress	-	0.46	-	-	-	-

Updated Feb 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.